Spots Global Cancer Trial Database for Study of D3S-002 as Monotherapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of D3S-002 as Monotherapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations
Official Title: A Phase 1, Open-label, Dose-escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose of D3S-002 Monotherapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations
Study ID: NCT05886920
Interventions
Study Description
Brief Summary: This first-in-human (FIH) study aims to assess the safety, tolerability, pharmacokinetics, and recommended phase 2 dose (RP2D) of D3S-002 given orally daily for 21-day cycles in adult subjects with advanced solid tumors with mitogen-activated protein kinase (MAPK) pathway mutations.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
D3 Bio Investigative Site, Detroit, Michigan, United States
D3 Bio Investigative Site, Blacktown, New South Wales, Australia
D3 Bio Investigative Site, Bedford Park, South Australia, Australia
D3 Bio Investigative Site, Nedlands, Western Australia, Australia
D3 Bio Investigative Site, Beijing, Beijing, China
D3 Bio Investigative Site, Guangzhou, Guangdong, China
D3 Bio Investigative Site, Harbin, Heilong Jiang, China
D3 Bio Investigative Site, Shanghai, Shanghai, China
D3 Bio Investigative Site, Hangzhou, Zhejiang, China
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
